ViaDerma, Inc. (OTCMKTS:VDRM) shares exploded in 2017 trading from the triple zero sub penny to .06 on huge volume. It has an interesting product line, but shareholders, traders and investors seem to care more about the momentum plays in these smaller triple zero stocks hoping they would do exactly what ViaDerma has done in 2017.
The company is a specialty pharmaceutical business devoted to bringing new products to market and they recently announced they filed with the (FDA) Food and Drug Administration for a new over the counter or OTC version of its “Premature Ejaculation Drug”. The new “OTC Drug” should have FDA registration approval in approximately 8 weeks and the Company’s name of the new drug will portray prolonged endurance. The Company’s recent testing of the drug has proved to be successful in retarding the onset of ejaculation during sexual intercourse.
Viaderma Inc (OTCMKTS:VDRM) is aware the market for male sexual dysfunction is dominated by Viagra and Cialis – but both are taken orally for Erectile Dysfunction (ED). The Company’s alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.
This is another product in the “Go to Market Strategies” pipeline. The Company already has located a suitable distributor and is attempting to assure a solid strategy behind the launch once the FDA submission is approved. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several products. The Company continues its plan for an aggressive growth for 2017 and the years ahead.
Find out when $VDRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Premature ejaculation (PE) is the most common male sexual disorder, and it may have a profound negative impact on a man and his partner’s lives. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company.
In the US, topical sprays that treat PE are available OTC. In reported testing these types of products work on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment segment of the sexual dysfunction market has been estimated to be $1.3 Billion dollars for 2017. Also, reported, the market for these types of products could become larger than the tablet or oral (ED) market. The sales of the topical market are reportedly up from about $684 million dollars in 2010, based on the U.S. and European approval of several new products. The market is expected to increase in value by around 10.3% in 2017.
ViaDerma, Inc. (OTCMKTS:VDRM) is committed to bringing new products to market and licensing its innovative technology to the pharmaceutical industry in a wide variety of therapeutic areas. Shares in the stock have reacted to the sheer size of the industry itself as the company focuses on it’s lead product, Viabecline, which uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2014.
This may have been the catalyst behind much of the moves in share price. This arena has such growth opportunities related to treating inflammation with CDB’s. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For continuing coverage on shares of $VDRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!